The resurgence of tuberculosis has been characterized by the emergence of significant numbers of drug-resistant strains. Furthermore, microorganisms of the Mycobacterium avium complex, opportunistic pathogens common in AIDS patients, are inherently resistant to many traditional antimycobacterial agents (20, 23) . Hence, the development of novel drugs for the treatment of atypical infections by M. avium, Mycobacterium intracellulare, and multiple-drug-resistant Mycobacterium tuberculosis is urgently needed.
The mycobacterial cell wall is an effective barrier that contributes to drug resistance (45) . Inhibitors of cell wall biosynthesis not only are potential antimycobacterial agents but also increase mycobacterial susceptibility to other antimicrobial agents (36) . One inhibitor of cell wall synthesis is D-cycloserine (D-4-amino-isoxazolidone [DCS]), a cyclic structural analog of D-alanine (31) . D-Amino acids, especially D-alanine, D-glutamate, and D-aminopimelate, are important components of all bacterial cell walls, including those of mycobacteria. Alanine is usually available as the L stereoisomer, and the conversion to D-alanine by the cytoplasmic enzyme D-alanine racemase (25) is required for the initial step in the alanine branch of peptidoglycan biosynthesis. D-Alanine is converted to the dipeptide D-alanyl-D-alanine in a reaction catalyzed by D-alanyl:alanine synthetase (D-alanine ligase [30] ). In Escherichia coli, both D-alanine racemase and D-alanine ligase are targets of DCS (26, 31, 33) . Moreover, the biosynthesis of mycolyl-arabinogalactan-peptidoglycan complex is inhibited by DCS in M. tuberculosis (10) , and biochemical studies indicated that D-alanine ligase is one of the targets in mycobacteria (11) .
DCS is an effective antimycobacterial agent but is rarely prescribed and used only in combined therapies due to its adverse effects (21, 22, 54) . These side effects are due to binding of DCS to neuronal N-methyl aspartate receptors (44) and inhibition of enzymes that metabolize and synthesize the neurotransmitter ␥-aminobutyric acid (53) . Nevertheless, DCS is an excellent candidate for the development of a new generation of antibiotics. Two important considerations predict that rationally designed derivatives of DCS may be more efficacious antimicrobial agents. First, DCS targets participate in essential steps of cell wall synthesis. Second, DCS resistance has not yet become an important clinical problem. Therefore, the identification of DCS targets and the elucidation of the mechanisms leading to DCS resistance may contribute to the development of new therapeutics with fewer side effects and mechanisms of action which do not favor the emergence of resistance.
Few studies on the mode of action and mechanisms of DCS resistance in mycobacteria have been conducted. David (9) isolated and characterized step-wise DCS-resistant (DCS r ) mutants of M. tuberculosis and discovered mutants that showed either normal or reduced cellular permeability to DCS. It was hypothesized that mutants with normal uptake carried mutations in the D-alanine ligase gene, but no biochemical or molecular evidence in support of this hypothesis was provided.
Here we describe the first molecular genetic analysis of DCS resistance in mycobacteria, which led to the identification of one of the DCS targets and resistance mechanisms in Mycobacterium smegmatis. A spontaneous DCS r mutant strain of M. smegmatis exhibited a promoter-up mutation in the D-alanine racemase gene (alrA) which increased the levels of expression of the gene and determined a DCS r phenotype. Furthermore, transformants of M. intracellulare and M. bovis BCG with the M. smegmatis alrA gene carried in a multicopy vector had a DCS r phenotype, indicating that a similar mechanism of resistance may occur in pathogenic mycobacteria.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. Bacterial strains and plasmids used in this study are listed in Table 1 . E. coli strains were grown in Luria-Bertani broth or agar. M. intracellulare strains were grown as previously described (16) . M. smegmatis strains were grown at 37°C with shaking (200 rpm; Innova 4300 incubator shaker; New Brunswick Scientific, Edison, N.J.) in Middlebrook 7H9 broth (BBL Microbiology Systems, Cockeysville, Md.), LuriaBertani broth, or minimal medium (55) in the presence of 0.05% Tween 80. Tryptic soy agar base (Difco Laboratories, Detroit, Mich.) was used for growth of M. smegmatis on solid media. Spontaneous DCS-resistant M. smegmatis mutants were isolated by plating approximately 5.0 ϫ 10 9 exponentially growing cells on tryptic soy agar with 500 to 600 g of DCS ml
Ϫ1
. Since DCS is moderately unstable, agar plates containing DCS were kept at 4°C for a maximum of 2 days. The independent mutants GPM14 and GPM16 were isolated at 500 and 600 g ml
, respectively, from the susceptible parent strain mc 2 155 (Fig. 1) . To determine inhibition of colony formation, appropriate dilutions of exponentially growing cells (5.0 ϫ 10 8 to 1.0 ϫ 10 9 CFU ml
) were plated in triplicate onto agar containing a maximum of 1,500 g of DCS ml Ϫ1 for M. smegmatis or up to 250 g of DCS ml Ϫ1 for M. intracellulare. Regression analyses of bacterial titers at different DCS concentrations were conducted by using Proc Reg (SAS Institute, Cary, N.C.). The reduced model for the different bacterial strains was tested against the full model for lack of fit for each of the mycobacterial species tested. A significant lack of fit indicated that the responses to the DCS concentrations were different between the strains. If a significant lack of fit was determined when all the strains were considered, subsets of strains were also compared.
For D-alanine racemase assays, M. smegmatis cells were grown in minimal medium (55) to mid-exponential phase (ca. 3.0 ϫ 10 8 CFU ml
). For ␤-galactosidase assays, the M. smegmatis strains were grown in Middlebrook 7H9 broth to mid-exponential phase (ca. 3.0 ϫ 10 8 CFU ml Ϫ1 ). Transformation of E. coli and mycobacteria was carried out as described previously (16) . E. coli and M. intracellulare transformants were selected at 50 g of kanamycin ml Ϫ1 . M. smegmatis transformants were selected at either 10 g of kanamycin ml
Ϫ1 or 10 g of kanamycin (Sigma Chemical Co., St. Louis, Mo.) ml Ϫ1 plus 300 g of DCS (Sigma or Aldrich Chemical Co., Inc., Milwaukee, Wis.) ml
. Oligonucleotides, PCR amplifications, and probe labeling. The oligonucleotide primers (Ransom Hill Biosciences, Inc., Ramona, Calif.) for PCR amplification of the D-alanine racemase genes from pBUN66 and GPM14 were JIM-1 (5Ј-GNGAYYNYGGRTACACCGAGTTC-3Ј) and JIM-2 (5Ј-CGNCGRCG AGCNNCTCGAAATC-3Ј). The oligonucleotide primer pair for probe labeling by PCR was NAN-1 (5Ј-TCTGCGGCCTCTGGGACAATGGG-3Ј) and NAN-2 Ϫ1 under standard cycling temperatures (hot start at 95°C, denaturation at 94°C, annealing at 55°C, and polymerization at 72°C). For radioactive labeling, 10 cycles were run in the presence of 50 Ci of [␣-32 P]dATP. The Expand high-fidelity PCR system (Boehringer Mannheim Biochemicals, Indianapolis, Ind.) was used as recommended by the manufacturer.
Nucleic acid manipulations, DNA sequencing, and primer extension analysis. For restriction digestions, ligations, agarose gel electrophoresis, and Southern hybridizations under stringent conditions, standard procedures were followed as previously described (40) . Chromosomal DNA from M. intracellulare strains, M. paratuberculosis, and M. smegmatis was prepared as described previously (51) . Chromosomal DNA from BCG and M. tuberculosis was provided by W. R. Jacobs, Jr., and T. Weisbrod.
Total RNA from mc 2 155, GPM14, and GPM16 was isolated by following the procedure described by Bashyam and Tyagi (3) . Northern blotting was done as previously described (1) . Quantification of mRNA was carried out by capturing the images from the autoradiograms with a Kaiser RS-1 video camera and a Northern Light model 890 illuminator (Kaiser Optical Systems, Inc., Ann Arbor, Mich.) and analyzing the output with NIH Image 1.49 software. The levels of RNA were normalized by the amount of rRNA.
Sequencing reactions were carried out with the Taq DyeDeoxy FS terminator cycle sequencing kit (The Perkin-Elmer Corp., Norwalk, Conn.). The unincorporated dye terminators and primers were separated from the extension products by spin column purification (Centri-Sep; Princeton Separations, Adelphia, N.J.). The samples were dried, resuspended in loading buffer, heat denatured, and loaded in ABI model 377 DNA sequencers (Applied Biosystems, Foster City, Calif.). Each template was sequenced in its entirety in both orientations to prevent potential errors in sequencing. DNA sequencing and nucleotide sequence analyses were performed at the University of Minnesota's Advanced Genetic Analysis Center (St. Paul). Protein sequence analysis was performed with the Genetics Computer Group package (version 8.1), University of Wisconsin (13) .
For the assessment of promoter strength by ␤-galactosidase reporter gene assays, 1.8-kb DNA fragments were amplified with primers JIM-2 and JIM-3, the products were digested with ScaI and ClaI, and the resulting 0.5-kb fragments were directionally cloned into the ClaI and the blunt-ended PstI sites of pCV77.
The synthesis of blunt-ended termini was carried out with Pfu DNA polymerase as instructed by the supplier (Stratagene, La Jolla, Calif.). All constructs were verified by sequencing of the relevant regions.
Primer extension analysis of alrA mRNA was carried out as described previously (12) . The oligonucleotide NAN-3 (5Ј-ATCGATCACCGTCTGTGCCG ACGCC-3Ј) was radiolabeled with [␥-32 P]ATP by using T4 polynucleotide kinase (Promega). The reactions were extended with Moloney murine leukemia virus reverse transcriptase (Promega). Radioactivity in primer extension bands was quantified with a PhosphorImager by using ImageQuant software version 3.3 (Molecular Dynamics, Sunnyvale, Calif.).
M. smegmatis genomic libraries. An M. smegmatis mc 2 155 cosmid library was kindly provided by W. R. Jacobs, Jr. For M. smegmatis GPM16 genomic libraries, chromosomal DNA was partially digested with Sau3A, and fragments with an average size of 3.0 kb were purified from a 0.8% agarose gel and ligated into the BamHI site of the E. coli-Mycobacterium shuttle plasmid pMV262 (7), which carries the kanamycin-resistant marker and the strong promoter P hsp60 . The ligation mixture (approximately 1.0 g of vector DNA) was transformed into M. smegmatis mc 2 155. For selection of DCS resistance determinants, cells were plated on 10 g of kanamycin ml
Ϫ1 plus 300 g of DCS ml Ϫ1 and yielded two DCS-resistant clones. Parallel platings of the transformation mixture on 10 g of kanamycin ml
Ϫ1 indicated a transformation efficiency of 4 ϫ 10 4 . Plasmids were isolated from independent kanamycin-resistant transformants and analyzed in E. coli for the presence of M. smegmatis inserts. This analysis revealed approximately 10% recombinant plasmids. Hence, the two DCS-resistant clones resulted from a representative library of ca. 4,000 recombinants.
Preparation of crude cell extracts. Cells were harvested and concentrated 20-fold in 50 mM Tris-HCl (pH 8.0). Cells were kept on a salt-ice-water bath and sonicated with a Vibra-Cell model VC600 disrupter (Sonic and Materials, Inc., Danbury, Conn.). Sonication was carried out for 10 min at 80% power output and 50% duty cycle, and in the presence of one-third the final volume of type A-5 alumina (Sigma). The resulting extracts were centrifuged at 4°C in a JA-17 rotor (Beckman Instruments, Inc., Fullerton, Calif.) for 30 min at 15,000 rpm, dialyzed against 50 mM Tris-HCl (pH 8.0), and sterilized by filtration through a 0.22-mpore-size filter. The protein concentration was determined by the DC assay (Bio-Rad Laboratories, Richmond, Calif.) as recommended by the manufacturer.
Enzyme assays. D-Alanine racemase activity in crude extracts was assayed in the direction of the conversion of L-alanine into D-alanine by a modification of the coupled spectrophotometric method described by Wijsman (52) . Pilot experiments were performed to determine the amount of each extract and incubation times (15 min) resulting in a linear conversion of the substrate into the product. Crude cell extracts were incubated at 37°C in 1.0 ml each of reaction mixtures containing 50 mM Tris-HCl (pH 8.0), 0.1 mM pyridoxal phosphate (Sigma), and 15 mM L-alanine (Sigma). To start the reactions, crude cell extracts were added to prewarmed mixtures. For inhibition assays, DCS was added at 10, 50, or 100 g ml Ϫ1 . Reactions were terminated by boiling for 10 min. Subsequently, 0.25 mg of D-amino acid oxidase (Boehringer Mannheim), 0.2 mM NADH (Sigma), and 10 U of lactate dehydrogenease (Sigma) were added. The coupled reaction was measured by the change in absorbance at 340 nm after overnight incubation at 37°C. All controls and samples were measured in triplicate. For the calculation of specific activities, the background change in absorbance (obtained with boiling-inactivated extracts processed in an identical manner) was subtracted from the change in absorbance obtained with active extracts. From this net absorbance change (⌬A 340 ), the specific activity (in micromoles of L-alanine per minute per milligram) was calculated by using the following equation: [⌬A 340 /t]/[6.2 ϫ C P ], where t is time (in minutes), 6.2 is the constant used to convert from A 340 into micromoles (in milliliters per micromole, and C P is protein concentration (in milligrams per milliliter of reaction mixture). No net change in absorbance was detected with active extracts when L-alanine was omitted from the reaction mixtures.
The ␤-galactosidase activity was determined in crude extracts as described previously (29) . Pilot experiments were performed for each cell extract to determine the optimal incubation time and protein concentration resulting in a linear hydrolysis of ␤-o-nitrophenylgalactoside. Units of ␤-galactosidase activity per milligram were calculated as follows: (⌬A 420 of sample Ϫ ⌬A 420 of control) ϫ 380/(t ϫ A P ), where 380 is the constant used to convert from A 420 into ␤-galactosidase units. t is time (in minutes) at 28°C, and A P is amount of protein (in milligrams) in the reaction mixture.
Nucleotide sequence accession number. Sequence data corresponding to the M. smegmatis D-alanine racemase gene cloned in pBUN19 and flanking sequences appear in the EMBL/GenBank/DDBJ nucleotide sequence data libraries under accession no. U70872.
RESULTS
Cloning and characterization of M. smegmatis DCS resistance determinants. DCS r mutants of M. smegmatis were isolated, and a genomic library of a mutant strain was constructed in a multicopy plasmid. By using this type of cloning strategy, either wild-type genes producing a DCS r phenotype due to a gene dosage effect or genes with dominant mutations encoding proteins which are insensitive to drug inhibition can be isolated. However, this strategy does not readily identify mutations involved in DCS transport. In this work, two spontaneous DCS r mutants, GPM14 and GPM16, were isolated at 500 and 600 g of DCS ml Ϫ1 , respectively, from the DCS-sensitive (DCS s ) strain mc 2 155 with a frequency of 1.0 ϫ 10
Ϫ9
. These DCS r strains were identical to the parent strain with respect to generation time, colony morphology, phage susceptibility, and susceptibility to antimicrobial agents other than DCS, indicating that these mutants carry a mutation(s) specific for DCS resistance. The mutant strain GPM16 was selected for the construction of a genomic library.
The genomic library was constructed in E. coli-Mycobacterium shuttle plasmid pMV262, which replicates with a copy number of 5 to 10 in mycobacteria and carries the kanamycin resistance selection marker (7) ( Table 1 ). The library was transferred to the DCS s strain mc 2 155 for the isolation of transformants resistant to kanamycin and DCS. Plating of a representative library (approximately 4,000 recombinants) led to the isolation of a recombinant plasmid (pBUN19) carrying a 3.1-kb insert. Retransformation of the DCS s strain mc 2 155 with this plasmid resulted in 100% of the transformants displaying a DCS r phenotype, indicating that a DCS resistance determinant(s) was present in pBUN19.
The DCS r phenotypes of mutants, recombinants, and controls were characterized by the inhibition of colony formation at increasing DCS concentrations (Fig. 1) . The control group, strains mc 2 155 and mc 2 155(pMV262), had approximately the same susceptibility to DCS (P ϭ 0.80). Strains GPM14, GPM16, and mc 2 155(pBUN19) were significantly more resistant than the control group (P Ͻ 0.00001).
ORF and subcloning analysis of the DCS resistance determinant. Nucleotide sequence analysis of the 3,059-bp DNA insert from pBUN19 revealed two open reading frames (ORFs) (Fig. 2) . ORF1 (1,236 nucleotides) has significant homology with the E. coli glutamate decarboxylase gene, (gadS [28] , or gadA [42] ). ORF2 (1, 167 nucleotides) encodes a product with significant homology to D-alanine racemases from several microbial species. The M. smegmatis D-alanine racemase gene and its immediate flanking regions were sequenced. An initiation codon (ATG) at position 51 and a putative ribosomal binding site (GAGAT) separated from the initiation codon by 7 bp were identified. Subcloning experiments were performed to further localize the DCS r determinant within the 3.1-kb insert of pBUN19. The ScaI/HindIII DNA fragment subcloned in pBUN82, which contains the complete D-alanine racemase gene (alrA) but only a truncated glutamate decarboxylase gene (gadA), was sufficient for a DCS r phenotype (Fig. 2) . In contrast, subcloning of the 2.0-kb DraI/ClaI fragment in plasmid pBUN83, which contains the gadA gene, gave a DCS s phenotype. Furthermore, subcloning of DNA fragments into pMV262, which split alrA (plasmids pBUN25 and pBUN47D), resulted in DCS s transformants (Fig. 2) . Hence, alrA is necessary and sufficient to confer DCS r to mc 2 155. The presence of homologous alrA alleles in pathogenic mycobacteria was tested by Southern analysis with the D-alanine racemase gene amplified by PCR as a probe (Fig. 3) (14), E. coli (5, 27) , and Salmonella typhimurium (49, 50) and the putative enzyme from Haemophilus influenzae (15) . Multiple amino acid sequence alignments showed highly conserved domains: the amino acid sequence A 66 VVKANAYGHG 76 in the consensus, which contributes to the pyridoxal phosphate binding domain in the active site (18) , and the conserved lysine which covalently binds pyridoxal phosphate in the catalytic cycle (2, 39) . All the mycobacterial D-alanine racemases display a two-domain structure, as observed in the isozymes from S. typhimurium (19) . In this larger alignment, the consensus at the hinge region that links the two domains is defined as V 302 -YG--W 308 . Analysis of D-alanine racemase activity and the inhibitory effect of DCS in M. smegmatis. We determined the D-alanine racemase specific activity of cell extracts from the parent strain, i.e., mc 2 155, mutant GPM16, and recombinant strain mc 2 155 (pBUN19) (Fig. 5) . The D-alanine racemase activity in each cell extract was inhibited by DCS in a concentration-dependent manner. Degrees of inhibition by DCS were similar for all these strains (data not shown). These results confirmed that D-alanine racemase is one of the drug targets. Surprisingly, the mutant GPM16 displayed levels of D-alanine racemase and a pattern of DCS inhibition similar to that of the wild-type strain. Therefore, its resistance phenotype appears to be due to a mutation in a separate DCS resistance determinant, distinct from the D-alanine racemase gene. In contrast, the recombinant strain had a 15-fold-higher specific activity. We hypothesized that the resistance phenotype in the recombinant strain was the consequence of elevated expression of the wild-type D-alanine racemase gene harbored in the multicopy vector. To verify this hypothesis, a cosmid library of the wild-type strain mc 2 155 was screened with the objective of identifying and analyzing the D-alanine racemase gene. The recombinant plasmid pBUN66 was isolated by colony hybridization with the DraI-HindIII fragment from pBUN19 as a probe (see Materials and Methods). The wild-type D-alanine racemase nucleotide gene and flanking sequences in pBUN66 were PCR amplified and sequenced. The D-alanine racemase gene in pBUN66 was identical to the one cloned in pBUN19, confirming that the mutant GPM16 had a wild-type D-alanine racemase gene. Therefore, this result together with the biochemical data strongly suggests that the DCS-resistant phenotype of the recombinant strain mc 2 155(pBUN19) was due to an overexpression of the D-alanine racemase gene and not a mutation in the structural gene. Furthermore, the recombinant plasmid pBUN92 (Fig. 2) , which does not carry the P hsp60 promoter, exhibits a DCS r phenotype as well. Hence, multiple copies of the wild-type D-alanine racemase gene appear to cause the DCS r phenotype of the recombinant strain. In agreement with the E. coli (5) (accession no. U00006) and M. leprae (17) (accession no. U00020) designations, we propose the designation alrA for the M. smegmatis D-alanine racemase gene, which is constitutively expressed (6) .
Overproduction of D-alanine racemase is also a mechanism of resistance in spontaneous M. smegmatis DCS r mutants. Since the observation of the overproduction of D-alanine racemase in the recombinant strain mc 2 155(pBUN19) was the result of a laboratory manipulation, we analyzed four additional DCS r independent mutants derived from mc 2 155. The crude extract of one of these mutants, GPM14, displayed levels of D-alanine racemase specific activity similar to those displayed by the recombinant strain mc 2 155(pBUN19) (Fig. 5) . The spontaneous DCS r mutant GPM14 exhibited approximately 20-fold-greater D-alanine racemase specific activity than the DCS s strain mc 2 155. The D-alanine racemase activity of GPM14 was inhibited by DCS in a fashion similar to that of the wild-type enzyme. In agreement with the enzyme activity assays, Northern blot analysis demonstrated a 30-fold overexpression of D-alanine racemase alrA mRNA in GPM14 compared to that in strain mc 2 155 (data not shown). A promoter-up mutation leads to the overexpression of the D-alanine racemase (alrA) gene in M. smegmatis DCS r mutant GPM14. The D-alanine racemase allele from GPM14 was PCR amplified and sequenced. Nucleotide sequence analysis did not show any mutation within the structural gene but revealed a single base change, T for G, in the upstream noncoding regions. The identification of the DCS r mutant GPM14, which possessed an elevated level of D-alanine racemase specific activity but an unaltered D-alanine racemase structural gene, established solid evidence that overproduction of this enzyme could occur by a natural mechanism.
Mapping of the mRNA start site in mc 2 155 and GPM14 was carried out by primer extension analysis (Fig. 6) . In each case, two start sites, one nucleotide apart, were found 13 and 14 bp upstream from the amino acid start codon, with the product of the shorter sequence being more abundant. The point mutation in GPM14 was located within the putative Ϫ10 promoter [43] ); Bsubt, B. subtilis (accession no. M16207 [14] ); Mleprae, M. leprae (accession no. U00020 [17] ); Mtb, M. tuberculosis (accession no. Z77165 [35] ); Ecoli-Cat, E. coli (catabolic isozyme; accession no. L02948 [27] ); Styph-Cat, S. typhimurium (catabolic isozyme; accession no. K02119 [49] ); Styph-Bio, S. typhimurium (biosynthetic isozyme; accession no. M12847 [18] ); Ecoli-Bio, E. coli (biosynthetic isozyme; accession no. U00006 [5] ); and Hinf-Bio, H. influenzae (biosynthetic isozyme; accession no. L46206 [15] ).
box at position Ϫ13 in the short transcript. Quantification of radioactivity in the primer extension bands demonstrated that both the shorter and longer transcripts of GPM14 (DCS r ) were overproduced approximately 15-fold with respect to those in mc 2 155 (DCS s ). To assess whether the point mutation in the promoter region of the D-alanine racemase gene of mutant strain GPM14 was responsible for changes in the promoter strength, transcriptional fusions to a reporter gene were performed. The ScaIClaI fragments (Fig. 2) , which included approximately 500 bp of the noncoding region of the D-alanine racemase gene from wild-type (mc 2 155) and mutant (GPM14) strains, were subcloned into the promoter-probe vector pCV77 (Table 1) upstream from the promoterless lacZ gene. These promoter constructs were transformed into wild-type M. smegmatis mc 2 155, and ␤-galactosidase activities were measured. The expression from the construct containing the GPM14 alrA promoter was approximately 50-fold higher than the expression from the respective mc 2 155 promoter. These results (Table 2) confirmed that a point mutation, which increases the %AT of the putative Ϫ10 box of the alrA gene, led to a significant increase in the level of gene expression.
Overexpression of the M. smegmatis D-alanine racemase (alrA) gene from a multicopy plasmid in M. intracellulare and M. bovis BCG leads to a DCS-resistant phenotype. To determine if the overproduction of D-alanine racemase could also confer a DCS r phenotype in pathogenic mycobacteria, recombinant plasmid pBUN19 was electrotransformed into M. intracellulare mc 2 76 and M. bovis BCG. The susceptibilities of the wild-type and transformant strains to DCS are depicted in Fig.  7 . These mycobacterial species are inherently more susceptible to DCS than M. smegmatis. As illustrated, the M. intracellulare strain mc 2 76(pBUN19) is more resistant to DCS than the parent strain transformed with plasmid vector pMV262 (P Ͻ 0.01). Colony morphology changes were noticed at DCS concentrations higher than 40 g ml Ϫ1 in M. intracellulare. A similar profile was obtained with M. bovis BCG, where the transformant with plasmid pBUN19 was more resistant than the control strain carrying cloning vector pMV262 (P Ͻ 0.05). Taken together, these data indicate that multiple copies of a wild-type D-alanine racemase gene can confer a DCS-resistant phenotype in M. intracellulare and M. bovis BCG.
DISCUSSION
In this study, we identified a gene from M. smegmatis that confers a DCS-resistant phenotype to a wild-type DCS-sensitive host when cloned into a multicopy vector. This represents the first molecular genetic analysis of DCS targets in mycobacteria. The mechanisms of DCS resistance in mycobacteria have not been thoroughly investigated. Since DCS can inhibit several pyridoxal phosphate enzymes (31), the existence of more than one mechanism leading to DCS resistance is likely. In addition, multiple-step DCS r mutants of mycobacteria were isolated in previous studies (46) as well as in our laboratory. The mechanisms relevant to DCS resistance in mycobacteria are presented in the model depicted in Fig. 8 . DCS may enter the mycobacterial cell by either diffusion or uptake via a specific transporter (48) . Mutations in the transporter gene reducing DCS binding or eliminating the transporter from the cell surface may lead to reduced DCS uptake and increased DCS resistance. Similarly, a mutation in a gene coding for an efflux pump may lead to higher affinity for DCS, with the concomitant expulsion of the drug. Alternatively, it is possible that a mutational change could increase the affinity or the levels of a drug-detoxifying enzyme which would derivatize or hydrolyze DCS. The overproduction of a protein target(s) could lead to increased resistance due to the sequestration or removal of the 2 155 or GPM14 cells was annealed to an oligonucleotide of the alrA gene and extended as described in Materials and Methods. Lanes A, C, G, and T display a dideoxy sequencing ladder of the wild-type alrA gene generated with the same oligonucleotide primer. Nucleotides at the two start sites are indicated by asterisks. The target site for the mutation in the promoter region is boxed. drug by the excess target protein. The latter mechanism would effectively reduce the free intracellular DCS concentration, which would also protect other potential protein targets from drug inhibition. If DCS interacts with more than one target protein (such as D-alanine racemase and D-alanine ligase), it is unlikely that mutations in one of the structural genes alone would lead to primary DCS resistance. In this study, we presented evidence that one of the mechanisms of DCS resistance in M. smegmatis involves the overexpression of the alrA gene due to a promoter-up mutation. In agreement with our findings, a similar mechanism of DCS r involving the overproduction of either D-alanine racemase or D-alanine ligase enzyme activities, possibly mediated by wild-type products, was described for streptococci (38) .
We have shown that D-alanine racemase is a target of DCS and that a natural mechanism of resistance is the overproduction of the enzyme due to a promoter-up mutation. An interesting finding was that the original DCS r mutant, GPM16, used as a source of DNA for the cloning experiments did not possess elevated levels of D-alanine racemase. Hence, the resistance mechanism in GPM16 and three other mutants is not related to the D-alanine racemase determinant. We are currently investigating another DCS r clone carrying a different DCS resistance determinant (6) .
Soon after the introduction of DCS as an antituberculosis drug about 40 years ago, DCS r clinical isolates of M. tuberculosis were readily isolated (8) . Since those first trials, DCS has not been administered frequently or alone due to its toxicity in patients. As a consequence, the current panel of DCS r clinical isolates of pathogenic mycobacteria is limited and may not be representative of the situation that would arise in therapy with DCS. Once we identified a DCS r determinant in M. smegmatis and showed its conservation within the genus, we tested whether a similar mechanism of DCS resistance could occur in members of the pathogenic mycobacterial groups by transforming M. intracellulare and M. bovis BCG with a multicopy plasmid carrying the M. smegmatis alrA gene. DCS r transformants were obtained, suggesting that AlrA overproduction is a potential mechanism of DCS resistance in clinical isolates of M. tuberculosis and other pathogenic mycobacteria. Furthermore, the homology between M. smegmatis AlrA and the M. leprae and M. tuberculosis counterparts suggests a potential utility of M. smegmatis as a surrogate host for the study of the AlrA enzymes from pathogenic species.
Since racemases are absent from mammalian cells, these bacterial enzymes are excellent targets for antibiotic development (47) . Several compounds were developed but were never advanced into clinical use due to their toxicity in humans (32) . The D-alanine racemase gene of mycobacteria may be a powerful tool for the rational design of effective and less toxic DCS derivatives and D-alanine analogs against M. tuberculosis and other pathogenic mycobacteria. A structure-based layout in which computational and crystallography methods are combined would advance the rational design of a new generation of drugs. A key ingredient to the success of this strategy is the identification of the DCS lethal target(s) in pathogenic mycobacteria whose inhibition leads to cell death.
